Relay Therapeutics, Inc.
RLAY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $10,007 | $25,546 | $1,381 | $3,029 |
| % Growth | -60.8% | 1,749.8% | -54.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $10,007 | $25,546 | $1,381 | $3,029 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $319,089 | $330,018 | $246,355 | $172,650 |
| G&A Expenses | $76,592 | $74,950 | $65,978 | $57,386 |
| SG&A Expenses | $76,592 | $74,950 | $65,978 | $57,386 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$13,206 | -$6,422 | -$11,677 | $137,691 |
| Operating Expenses | $382,475 | $398,546 | $300,656 | $367,727 |
| Operating Income | -$372,468 | -$373,000 | -$299,275 | -$364,698 |
| % Margin | -3,722.1% | -1,460.1% | -21,670.9% | -12,040.2% |
| Other Income/Exp. Net | $34,760 | $31,027 | $8,766 | $826 |
| Pre-Tax Income | -$337,708 | -$341,973 | -$290,509 | -$363,872 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$337,708 | -$341,973 | -$290,509 | -$363,872 |
| % Margin | -3,374.7% | -1,338.7% | -21,036.1% | -12,012.9% |
| EPS | -2.36 | -2.79 | -2.59 | -3.82 |
| % Growth | 15.4% | -7.7% | 32.2% | – |
| EPS Diluted | -2.36 | -2.79 | -2.59 | -3.82 |
| Weighted Avg Shares Out | 142,868 | 122,577 | 112,234 | 95,137 |
| Weighted Avg Shares Out Dil | 142,868 | 122,577 | 112,234 | 95,137 |
| Supplemental Information | – | – | – | – |
| Interest Income | $34,746 | $31,045 | $8,786 | $830 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $5,464 | $5,269 | $4,130 | $3,925 |
| EBITDA | -$380,210 | -$374,153 | -$306,822 | -$223,082 |
| % Margin | -3,799.4% | -1,464.6% | -22,217.4% | -7,364.9% |